Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females of couples with an indication for Controlled Ovarian Stimulation (COS) and in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI);~* \>=18 and \<=36 years of age at the time of signing informed consent;~* Body weight \> 60 and \<=90 kg and body mass index (BMI) \>=18 and \<=32 kg/m\^2;~* Normal menstrual cycle length: 24-35 days;~* Availability of ejaculatory sperm (use of donated and/or cryopreserved sperm is allowed);~* Willing and able to sign informed consent.~Exclusion Criteria:~* History of/or any current (treated) endocrine abnormality;~* History of ovarian hyper-response or ovarian hyperstimulation syndrome~(OHSS);~* History of/or current polycystic ovary syndrome (PCOS);~* More than 20 basal antral follicles \<11 mm (both ovaries combined) as measured on ultrasound scan (USS) in the early follicular phase (menstrual cycle day 2-5);~* Less than 2 ovaries or any other ovarian abnormality (including endometrioma \> 10 mm; visible on USS);~* Presence of unilateral or bilateral hydrosalphinx (visible on USS);~* Presence of any clinically relevant pathology affecting the uterine cavity or fibroids \>=5 cm;~* More than three unsuccessful IVF cycles since the last established ongoing pregnancy (if applicable);~* History of non- or low ovarian response to FSH/ human menopausal gonadotropin (hMG) treatment;~* History of recurrent miscarriage (3 or more, even when unexplained);~* FSH \> 12 IU/L or LH \> 12 IU/L as measured by the local laboratory (sample taken during the early follicular phase: menstrual cycle day 2-5);~* Any clinically relevant abnormal laboratory value based on a sample taken during the screening phase;~* Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts);~* Recent history of/or current epilepsy, human immunodeficiency virus (HIV) infection, diabetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary disease;~* Abnormal karyotyping of the patient or her partner (if karyotyping is performed);~* Smoking more than 5 cigarettes per day;~* History or presence of alcohol or drug abuse within 12 months prior to signing informed consent;~* Previous use of Org 36286;~* Use of hormonal preparations within 1 month prior to randomization;~* Hypersensitivity to any of the concomitant medication prescribed as part of the treatment regimen in this protocol;~* Administration of investigational drugs within three months prior to signing informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: f

Study Arms:
- 150 µg Corifollitropin Alfa (Type: EXPERIMENTAL): Participants received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (org 36286) on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recFSH; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were administered from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles \>= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses.
- 200 IU recFSH (Type: ACTIVE_COMPARATOR): Participants received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were given from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was administered when 3 follicles \>= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses.

Based on this trial design, predict the completion outcome and termination type (if applicable).